Pfizer files for Patent on Known Substance
This post examines Pfizer’s patent application on a known substance and the Indian Patent Office’s refusal in light of Section 3d and the Novartis decision. It discusses whether…
Patentability
43 articles
Pfizer falls prey to Section 3(d)
This post analyses the Indian Patent Office’s rejection of Pfizer’s Tofacitinib patent under Section 3(d). The decision addresses issues of novelty, inventive step, and the requirement for evidence…
ECJ Stems “Stem Cell” Patents
The ECJ has held that patents involving embryonic stem cells requiring destruction of human embryos are unpatentable in Europe. This post examines the legal and ethical reasoning behind…